Products - Breast cancer | Topic

Showing 23 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
14 April 2025
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 May 2025
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 June 2025
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 September 2025
Familial Breast Cancer: initial assessment and genetic testing (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
31 January 2027
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Breast cancer guidelines
Status:
In development
Programme:
NICE Hub
Expected publication date:
TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Advanced breast cancer: diagnosis and management (Partial update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

What we do

Into practice

Who we are

Breast cancer Products

Showing 23 products

Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)

Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]

Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

Familial Breast Cancer: initial assessment and genetic testing (update)

Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]

Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]

Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

Breast cancer guidelines

Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065

Advanced breast cancer: diagnosis and management (Partial update)

Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]

Quality standards

Indicators

Get support from NICE

Learn how we evaluate technologies

Register your product

Find published and proposed evaluations

Our programmes

Get involved

What we do

Into practice

Who we are

Breast cancer Products

Showing 23 products